| Phyllis M Chen, MD | |
|
Emergency Dept., Whidden Memorial Hospital, 103 Garland Street, Everett, MA 02149 | |
| (617) 389-6270 | |
| Not Available |
| Full Name | Phyllis M Chen |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | Emergency Dept., Whidden Memorial Hospital, Everett, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407800550 | NPI | - | NPPES |
| 2104725 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 223658 (Massachusetts) | Secondary |
| 207R00000X | Internal Medicine | 223658 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Melrosewakefield Healthcare | Melrose, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hallmark Health Urgent Care Physicians Llc | 1153557616 | 20 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
| Entity Name | Melrose Wakefield Emergency Physicians, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790730539 PECOS PAC ID: 0244143006 Enrollment ID: O20031107000277 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
| Entity Name | Henry Heywood Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205823879 PECOS PAC ID: 1658262605 Enrollment ID: O20040322000360 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
| Entity Name | Athol Memorial Hospital Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336120047 PECOS PAC ID: 7911959846 Enrollment ID: O20050218000228 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
| Entity Name | Hallmark Health Urgent Care Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184066912 PECOS PAC ID: 1153557616 Enrollment ID: O20131112001050 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Phyllis M Chen, MD Emergency Dept., Whidden Memorial Hospital, 103 Garland Street, Everett, MA 02149 Ph: (617) 389-6270 | Phyllis M Chen, MD Emergency Dept., Whidden Memorial Hospital, 103 Garland Street, Everett, MA 02149 Ph: (617) 389-6270 |
News Archive
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
› Verified 1 days ago
Dmitriy Kireyev, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 781-394-7731 | |
Serena H Chao, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-394-7703 | |
Muge M Erkan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland Street, Pulmonary Assoc. Boston, Everett, MA 02149 Phone: 617-389-4666 | |
Dr. Wayne Crawford Draper, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 135 Santilli Highway, Suite 310, Everett, MA 02149 Phone: 617-654-7503 | |
Donald M Kaplan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-389-4666 | |
Kimberly H. Kinaka, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-381-5061 | |
Dr. David Yut-chee Ting, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 19-21 Norwood St Evt, Everett, MA 02149 Phone: 617-394-7500 Fax: 617-394-7576 |